Jennifer A Ohtola1, Noor M Khaskhely1, Jessica L Saul-Mcbeth1, Anita S Iyer1, David J Leggat1, Sadik A Khuder2, M A Julie Westerink3. 1. Department of Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States. 2. Department of Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States; Department of Public Health and Preventative Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States. 3. Department of Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States; Department of Pathology, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States; Department of Medical Microbiology and Immunology, University of Toledo College of Medicine & Life Sciences, Toledo, OH, United States. Electronic address: westerin@musc.edu.
Abstract
BACKGROUND: Advanced age and human immunodeficiency virus (HIV) infection are associated with increased pneumococcal disease risk. The impact of these factors on cellular responses to vaccination is unknown. METHODS: HIV-infected (HIV+) individuals 50-65 years old with CD4(+) Tcells/μl (CD4) >200 on antiretroviral therapy (ART) ≥1 year received either the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine (PCV/PPV) or PPV only. HIV-uninfected (HIV-) controls received PCV/PPV. Phenotype distribution and surface expression of complement receptor CD21 and tumor necrosis factor superfamily receptors (TNFRs) were compared on serotype-specific B cells postvaccination. RESULTS: Postvaccination serotype-specific B cell percentages were significantly lower in HIV+ PCV/PPV compared to PPV groups, but similar between HIV+ or HIV- PCV/PPV groups. Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)(+) serotype-specific B cell percentages were significantly decreased in HIV+ PCV/PPV compared to PPV groups. CD21(+) serotype-specific B cells were significantly higher in HIV- compared to HIV+ PCV/PPV groups. CONCLUSIONS: An initial dose of PCV reduced the frequency, but not phenotype distribution, of serotype-specific B cells and also lowered TACI expression in aging HIV+ subjects postvaccination with PPV. These findings suggest that PCV does not enhance cellular responses to revaccination with PPV. Published by Elsevier Ltd.
BACKGROUND: Advanced age and humanimmunodeficiency virus (HIV) infection are associated with increased pneumococcal disease risk. The impact of these factors on cellular responses to vaccination is unknown. METHODS:HIV-infected (HIV+) individuals 50-65 years old with CD4(+) Tcells/μl (CD4) >200 on antiretroviral therapy (ART) ≥1 year received either the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine (PCV/PPV) or PPV only. HIV-uninfected (HIV-) controls received PCV/PPV. Phenotype distribution and surface expression of complement receptor CD21 and tumor necrosis factor superfamily receptors (TNFRs) were compared on serotype-specific B cells postvaccination. RESULTS: Postvaccination serotype-specific B cell percentages were significantly lower in HIV+ PCV/PPV compared to PPV groups, but similar between HIV+ or HIV- PCV/PPV groups. Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)(+) serotype-specific B cell percentages were significantly decreased in HIV+ PCV/PPV compared to PPV groups. CD21(+) serotype-specific B cells were significantly higher in HIV- compared to HIV+ PCV/PPV groups. CONCLUSIONS: An initial dose of PCV reduced the frequency, but not phenotype distribution, of serotype-specific B cells and also lowered TACI expression in aging HIV+ subjects postvaccination with PPV. These findings suggest that PCV does not enhance cellular responses to revaccination with PPV. Published by Elsevier Ltd.
Entities:
Keywords:
Aging; B cells; HIV infection; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; Streptococcus pneumoniae
Authors: Ole S Søgaard; Nicolai Lohse; Zitta B Harboe; Rasmus Offersen; Anne R Bukh; Heather L Davis; Henrik C Schønheyder; Lars Østergaard Journal: Clin Infect Dis Date: 2010-07-01 Impact factor: 9.079
Authors: Marcus Odendahl; Henrik Mei; Bimba F Hoyer; Annett M Jacobi; Arne Hansen; Gwendolin Muehlinghaus; Claudia Berek; Falk Hiepe; Rudi Manz; Andreas Radbruch; Thomas Dörner Journal: Blood Date: 2004-10-26 Impact factor: 22.113
Authors: David J Leggat; Anita S Iyer; Jennifer A Ohtola; Sneha Kommoori; Joan M Duggan; Claudiu A Georgescu; Sadik A Khuder; Noor M Khaskhely; Ma Julie Westerink Journal: J AIDS Clin Res Date: 2015-02
Authors: Thomas G Johannesson; Ole S Søgaard; Martin Tolstrup; Mikkel S Petersen; Jens M Bernth-Jensen; Lars Østergaard; Christian Erikstrup Journal: PLoS One Date: 2012-07-30 Impact factor: 3.240
Authors: Jennifer A Ohtola; Jessica L Saul-McBeth; Anita S Iyer; David J Leggat; Sadik A Khuder; Noor M Khaskhely; Ma Julie Westerink Journal: J AIDS Clin Res Date: 2016-03-14